Moreover, The ECHO-301 trial was the first phase 3 trial investigating the effect of anti-IDO and anti-PD1 therapy in melanoma; however, the trial itself had significant limitations and showed no survival benefit (49, 50). The gene discussed is PDCD1; the disease is melanoma.